Park Place Capital Corp Reduces Stock Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Park Place Capital Corp lowered its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 33.3% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 904 shares of the biopharmaceutical company’s stock after selling 451 shares during the period. Park Place Capital Corp’s holdings in Halozyme Therapeutics were worth $43,000 at the end of the most recent reporting period.

Other institutional investors also recently added to or reduced their stakes in the company. GAMMA Investing LLC raised its stake in Halozyme Therapeutics by 67.7% during the 3rd quarter. GAMMA Investing LLC now owns 867 shares of the biopharmaceutical company’s stock valued at $50,000 after acquiring an additional 350 shares during the last quarter. Toth Financial Advisory Corp acquired a new position in Halozyme Therapeutics during the third quarter worth $57,000. FSC Wealth Advisors LLC purchased a new stake in shares of Halozyme Therapeutics in the 3rd quarter worth about $65,000. CWM LLC lifted its holdings in shares of Halozyme Therapeutics by 77.5% in the third quarter. CWM LLC now owns 1,530 shares of the biopharmaceutical company’s stock valued at $88,000 after purchasing an additional 668 shares in the last quarter. Finally, Farther Finance Advisors LLC lifted its stake in Halozyme Therapeutics by 173.6% in the 3rd quarter. Farther Finance Advisors LLC now owns 1,620 shares of the biopharmaceutical company’s stock valued at $93,000 after buying an additional 1,028 shares in the last quarter. Institutional investors and hedge funds own 97.79% of the company’s stock.

Insider Activity at Halozyme Therapeutics

In other news, Director Jeffrey William Henderson sold 10,000 shares of Halozyme Therapeutics stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $50.01, for a total transaction of $500,100.00. Following the sale, the director now owns 43,611 shares of the company’s stock, valued at approximately $2,180,986.11. The trade was a 18.65 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 2.40% of the company’s stock.

Wall Street Analysts Forecast Growth

HALO has been the topic of several analyst reports. Wells Fargo & Company decreased their price target on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating on the stock in a research note on Monday, January 13th. JMP Securities boosted their price target on Halozyme Therapeutics from $72.00 to $73.00 and gave the company a “market outperform” rating in a research report on Friday, November 1st. Cowen reissued a “buy” rating on shares of Halozyme Therapeutics in a research report on Friday, October 18th. HC Wainwright raised their target price on Halozyme Therapeutics from $68.00 to $70.00 and gave the company a “buy” rating in a report on Friday, January 10th. Finally, Piper Sandler lifted their price target on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a “neutral” rating in a research note on Friday, January 10th. Four investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat.com, Halozyme Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $60.89.

Halozyme Therapeutics Price Performance

HALO opened at $55.63 on Friday. The company has a quick ratio of 9.15, a current ratio of 10.36 and a debt-to-equity ratio of 3.32. The company’s 50-day moving average price is $49.36 and its 200 day moving average price is $54.18. The firm has a market cap of $7.08 billion, a price-to-earnings ratio of 18.42, a price-to-earnings-growth ratio of 0.42 and a beta of 1.24. Halozyme Therapeutics, Inc. has a fifty-two week low of $33.15 and a fifty-two week high of $65.53.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.